Dong, Ruocheng
Denier-Fields, Diandra N.
Van Hulle, Carol A.
Kollmorgen, Gwendlyn
Suridjan, Ivonne
Wild, Norbert
Lu, Qiongshi
Anderson, Rozalyn M.
Zetterberg, Henrik
Blennow, Kaj
Carlsson, Cynthia M.
Johnson, Sterling C.
Engelman, Corinne D. http://orcid.org/0000-0003-4750-5607
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01AG27161, R01AG054047, R21AG067092)
Article History
Received: 19 May 2022
Accepted: 5 March 2023
First Online: 25 March 2023
Declarations
:
: Gwendlyn Kollmorgen and Norbert Wild are full-time employees of Roche Diagnostics GmbH. Ivonne Suridjan is a full-time employee of Roche Diagnostics International Ltd and holds non-voting equities in F. Hoffmann-La Roche. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. SJ received grants from the NIH during the conduct of the study and personal fees from Roche Diagnostics outside the submitted work.
: All participants provided signed informed consent before participation.
: This study was conducted with the approval of the University of Wisconsin Institutional Review Board.